American Journal of Physiology-Heart and Circulatory Physiology · 2001 · 76 citations · 28 references
Life SciencesPharmacologyPhysiologyCell SignalingElectrophysiologySignal TransductionCardiovascular PharmacologyIon Channel PharmacologyIon Channel PhysiologyIon Channel RegulationIon ChannelsPotassium Channel BiophysicsChannelsCyclic Adenosine Monophosphate PathwayCyclic Adenosine Monophosphate SignalingPatch Clamp TechniquesPotassium Channel BlockadeVascular Smooth Muscle PharmacologyVascular Smooth Muscle RegulationVoltage-clamp Techniques
The vasoconstrictor angiotensin II (ANG II) inhibits several types of K(+) channels. We examined the inhibitory mechanism of ANG II on voltage-gated K(+) (K(V)) currents (I(K(V))) recorded from isolated rat arterial smooth muscle using patch-clamp techniques. Application of 100 nM ANG II accelerated the activation of I(K(V)) but also caused inactivation. These effects were abolished by the AT(1) receptor antagonist losartan. The protein kinase A (PKA) inhibitor Rp-cyclic 3',5'-hydrogen phosphothioate adenosine (100 microM) and an analog of diacylglycerol, 1,2-dioctanyoyl-rac-glycerol (2 microM), caused a significant reduction of I(K(V)). Furthermore, the combination of 5 microM PKA inhibitor peptide 5-24 (PKA-IP) and 100 microM protein kinase C (PKC) inhibitor peptide 19-27 (PKC-IP) prevented the inhibition by ANG II, although neither alone was effective. The ANG II effect seen in the presence of PKA-IP remained during addition of the Ca(2+)-dependent PKC inhibitor Gö6976 (1 microM) but was abolished in the presence of 40 microM PKC-epsilon translocation inhibitor peptide. These results demonstrate that ANG II inhibits K(V) channels through both activation of PKC-epsilon and inhibition of PKA.
28